Trial | NCT02627131  Report issue

Title

Autologous Bone Marrow Stem Cell Therapy for Autism
Autologous Bone Marrow Stem Cell Therapy for Autism: An Open Label Uncontrolled Clinical Trial

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    24
The aim of this study was to evaluate the safety and effectiveness of autologous bone marrow mononuclear stem cells in the management of autism.
The aim of this study was to evaluate the safety and effectiveness of autologous bone marrow mononuclear stem cells in the management of autism of 24 patients at Vinmec International Hospital, Hanoi, Vietnam
Study Started
Apr 30
2014
Primary Completion
Dec 31
2015
Study Completion
Dec 31
2015
Last Update
Dec 10
2015
Estimate

Biological Autologous Bone Marrow Mononuclear Cells

Transplantation of Autologous Bone Marrow Mononuclear Cells

Stem cell transplantation Experimental

2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward

Criteria 

Inclusion Criteria:

- Confirmed diagnosis of autism according to the Diagnostic and Statistical Manual-IV (DSM-IV) diagnostic criteria for autistic disorder

Exclusion Criteria:

Epilepsy
Hydrocephalus with ventricular drain
Coagulation disorders
Allergy to anesthetic agents
Severe health conditions such as cancer, failure of heart, lung, liver or kidney
Active infections
Severe psychiatric disorders
No Results Posted